Research ExplorerPublicationsAng-2 is a potential molecular marker for lymphatic metastas...

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer

Standard

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer. / Volk, Annabelle; Legler, Karen; Hamester, Fabienne; Kuerti, Sascha; Eylmann, Kathrin; Rossberg, Maila; Schmalfeldt, Barbara; Oliveira-Ferrer, Leticia.

In: J CANCER RES CLIN, Vol. 149, No. 17, 11.2023, p. 15957-15967.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Volk, A, Legler, K, Hamester, F, Kuerti, S, Eylmann, K, Rossberg, M, Schmalfeldt, B & Oliveira-Ferrer, L 2023, 'Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer', J CANCER RES CLIN, vol. 149, no. 17, pp. 15957-15967. https://doi.org/10.1007/s00432-023-05354-1

APA

Volk, A., Legler, K., Hamester, F., Kuerti, S., Eylmann, K., Rossberg, M., Schmalfeldt, B., & Oliveira-Ferrer, L. (2023). Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer. J CANCER RES CLIN, 149(17), 15957-15967. https://doi.org/10.1007/s00432-023-05354-1

Vancouver

Volk A, Legler K, Hamester F, Kuerti S, Eylmann K, Rossberg M et al. Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer. J CANCER RES CLIN. 2023 Nov;149(17):15957-15967. https://doi.org/10.1007/s00432-023-05354-1

Bibtex

@article{d14ab41182394c219b01f4330f5cefac,
title = "Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer",
abstract = "PURPOSE: In ovarian cancer, there are two main routes of metastasis, namely intraperitoneal and retroperitoneal. Their biologic background is poorly understood. Identifying molecular markers involved might enable the development of tailored therapy regimens. Moreover, no reliable markers for response to anti-angiogenic treatment with bevacizumab are yet established. Angiopoietin-2 (Ang-2) is an angiogenic growth factor, involved in lymphatic activation and is associated with tumor progression. Here, we assessed the potential of Ang-2 as a molecular marker in metastasis and treatment of ovarian cancer.METHODS: In our study, quantitative and qualitative protein Ang-2 expression in tumor tissue of ovarian cancer patients was analyzed by Western blot (n = 138) and immunohistochemistry (n = 58). Further, Ang-2 levels in blood samples were quantified in enzyme-linked immunosorbent assay (n = 38). Expression levels of different tumor spread patterns were evaluated, and survival analyses were made.RESULTS: We observed that Ang-2 expression is significantly higher in tumors with retroperitoneal dissemination (pT1a-pT3b, pN1) compared to those showing intraperitoneal tumor growth (pT3c, pN0). In addition, patients with high Ang-2 expression have significantly longer overall survival compared to patients with low Ang-2 expression. Patients with high Ang-2 expression benefit significantly from therapy with bevacizumab.CONCLUSION: All in all, Ang-2 may serve as a molecular marker for patients with tumors prone to spread to lymph nodes and for patients who might benefit from bevacizumab therapy.",
keywords = "Humans, Female, Bevacizumab/therapeutic use, Lymphatic Metastasis, Angiopoietin-2/metabolism, Ovarian Neoplasms/pathology, Biomarkers",
author = "Annabelle Volk and Karen Legler and Fabienne Hamester and Sascha Kuerti and Kathrin Eylmann and Maila Rossberg and Barbara Schmalfeldt and Leticia Oliveira-Ferrer",
note = "{\textcopyright} 2023. The Author(s).",
year = "2023",
month = nov,
doi = "10.1007/s00432-023-05354-1",
language = "English",
volume = "149",
pages = "15957--15967",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "17",

}

RIS

TY - JOUR

T1 - Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer

AU - Volk, Annabelle

AU - Legler, Karen

AU - Hamester, Fabienne

AU - Kuerti, Sascha

AU - Eylmann, Kathrin

AU - Rossberg, Maila

AU - Schmalfeldt, Barbara

AU - Oliveira-Ferrer, Leticia

N1 - © 2023. The Author(s).

PY - 2023/11

Y1 - 2023/11

N2 - PURPOSE: In ovarian cancer, there are two main routes of metastasis, namely intraperitoneal and retroperitoneal. Their biologic background is poorly understood. Identifying molecular markers involved might enable the development of tailored therapy regimens. Moreover, no reliable markers for response to anti-angiogenic treatment with bevacizumab are yet established. Angiopoietin-2 (Ang-2) is an angiogenic growth factor, involved in lymphatic activation and is associated with tumor progression. Here, we assessed the potential of Ang-2 as a molecular marker in metastasis and treatment of ovarian cancer.METHODS: In our study, quantitative and qualitative protein Ang-2 expression in tumor tissue of ovarian cancer patients was analyzed by Western blot (n = 138) and immunohistochemistry (n = 58). Further, Ang-2 levels in blood samples were quantified in enzyme-linked immunosorbent assay (n = 38). Expression levels of different tumor spread patterns were evaluated, and survival analyses were made.RESULTS: We observed that Ang-2 expression is significantly higher in tumors with retroperitoneal dissemination (pT1a-pT3b, pN1) compared to those showing intraperitoneal tumor growth (pT3c, pN0). In addition, patients with high Ang-2 expression have significantly longer overall survival compared to patients with low Ang-2 expression. Patients with high Ang-2 expression benefit significantly from therapy with bevacizumab.CONCLUSION: All in all, Ang-2 may serve as a molecular marker for patients with tumors prone to spread to lymph nodes and for patients who might benefit from bevacizumab therapy.

AB - PURPOSE: In ovarian cancer, there are two main routes of metastasis, namely intraperitoneal and retroperitoneal. Their biologic background is poorly understood. Identifying molecular markers involved might enable the development of tailored therapy regimens. Moreover, no reliable markers for response to anti-angiogenic treatment with bevacizumab are yet established. Angiopoietin-2 (Ang-2) is an angiogenic growth factor, involved in lymphatic activation and is associated with tumor progression. Here, we assessed the potential of Ang-2 as a molecular marker in metastasis and treatment of ovarian cancer.METHODS: In our study, quantitative and qualitative protein Ang-2 expression in tumor tissue of ovarian cancer patients was analyzed by Western blot (n = 138) and immunohistochemistry (n = 58). Further, Ang-2 levels in blood samples were quantified in enzyme-linked immunosorbent assay (n = 38). Expression levels of different tumor spread patterns were evaluated, and survival analyses were made.RESULTS: We observed that Ang-2 expression is significantly higher in tumors with retroperitoneal dissemination (pT1a-pT3b, pN1) compared to those showing intraperitoneal tumor growth (pT3c, pN0). In addition, patients with high Ang-2 expression have significantly longer overall survival compared to patients with low Ang-2 expression. Patients with high Ang-2 expression benefit significantly from therapy with bevacizumab.CONCLUSION: All in all, Ang-2 may serve as a molecular marker for patients with tumors prone to spread to lymph nodes and for patients who might benefit from bevacizumab therapy.

KW - Humans

KW - Female

KW - Bevacizumab/therapeutic use

KW - Lymphatic Metastasis

KW - Angiopoietin-2/metabolism

KW - Ovarian Neoplasms/pathology

KW - Biomarkers

U2 - 10.1007/s00432-023-05354-1

DO - 10.1007/s00432-023-05354-1

M3 - SCORING: Journal article

C2 - 37684509

VL - 149

SP - 15957

EP - 15967

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 17

ER -